Epirubicin, cisplatin and docetaxel combination therapy for metastatic gastric cancer

Annals of Oncology

Volumn 16, Issue 9, 2005, Pages 1498-1502

  Di Lauro, L ^a   Belli, F ^a   Arena, M G ^b   Carpano, S ^a   Paoletti, G ^a   Giannarelli, D ^c   Lopez, M ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b San Giuseppe Hospital   (Italy)

^c Toraldo Hospital   (Italy)

Author keywords

Cisplatin; Docetaxel; Epirubicin; Metastatic gastric cancer

Indexed keywords

CISPLATIN; DEXAMETHASONE; DOCETAXEL; EPIRUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; SEROTONIN ANTAGONIST;

ADULT; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BOLUS INJECTION; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLUID RETENTION; HUMAN; MALE; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; STOMACH ADENOCARCINOMA; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; EPIRUBICIN; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; STOMACH NEOPLASMS; TAXOIDS;

EID: 24044537615     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi281     Document Type: Article

References (24)

1. Parkin DM, Bray F, Ferlay J et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Wöhrer SS, Raderer M, Hejna M. Palliative chemotherapy for advanced gastric cancer. Ann Oncol 2004; 15: 1585-1595.
3. Bleiberg H. CPT-11 in gastrointestinal cancer. Eur J Cancer 1999; 35: 371-379.
4. Kohne CH, Thuss-Patience P, Catane R et al. Final results of a phase II trial of CPT-11 in patients with advanced gastric cancer. Proc Am Soc Clin Oncol 1999; 18: 258a (Abstr 993).
5. Louvet C, André T, Tigaud JM et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 2002; 20: 4543-4548.
6. Al-Batran SE, Atmaca A, Hegewisch-Becker S et al. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol 2004; 22: 658-663.
7. Koizumi W, Saigenji K, Ujiie S et al. A pilot phase II study of capecitabine in advanced or recurrent gastric cancer. Oncology 2003; 64: 232-236.
8. Van Cutsem E. The treatment of advanced gastric cancer: New findings on the activity of taxanes. Oncologist 2004; 9 (Suppl 2): 9-15.
9. Crown J, O'Leary M. The taxanes: An update. Lancet 2000; 355: 1176-1178.
10. Roth AD, Ajani J. Docetaxel-based chemotherapy in the treatment of gastric cancer. Ann Oncol 2003; 14 (Suppl 2): 41-44.
11. Roth AD, Maibach R, Martinelli G et al. Docetaxel (Taxotere® -cisplatin (TC): An effective drug combination in gastric carcinoma. Ann Oncol 2000; 11: 301-306.
12. Ridwelski K, Gebauer T, Fahlke J et al. Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol 2001; 12: 47-51.
13. André T, Louvet C, Ychou M et al. Docetaxel-epirubicin as second-line treatment for patient with advanced gastric cancer. Proc Am Soc Clin Oncol 1999; 18: 277a (Abstr 1062).
14. Pagani O, Sessa C, Nolè F et al. Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: A multicentric phase I-II study. Ann Oncol 2000; 11: 985-991.
15. Price TH, Chatta GS, Dale DC et al. Effect of recombinant granulocyte colony-stimulating factor on neutrophil kinetics in normal young and elderly humans. Blood 1996; 88: 335-340.
16. Therasse P, Arbuck SG, Eisenhauer E et al. New guidelines to evaluate the response to treatment in solid tumours. J Natl Cancer Inst 2000; 92: 205-216.
17. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10.
18. Lee SH, Kang WK, Park J et al. Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer. Br J Cancer 2004; 91: 18-22.
19. Webb A, Cunningham D, Scarffe JH et al. Randomized trial comparing epirubicin, cisplatin and fluorouracil versus fluorouracil, doxorubicin and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15: 261-267.
20. Ross P, Nicolson M, Cunningham D et al. Prospective randomized trial comparing mitomycin, cisplatin and protracted venous-infusion fluorouracil (PVI-5FU) with epirubicin, cisplatin and PVI-FU in advanced esophagogastric cancer. J Clin Oncol 2002; 20: 1996-2004.
21. Lacave AJ, Baron FJ, Anton LM et al. Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: A phase II trial. Ann Oncol 1991; 2: 751-754.
22. Rougier P, Ducreux M, Mahjoubi M et al. Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis. Eur J Cancer 1994; 30A: 1263-1269.
23. Moiseyenko V, Ajani JA, Tjulandin SA et al. Final results of a randomized controlled phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC). J Clin Oncol 2005; 23 (16S): 308s (Abstr 4002).
24. Roth DA, Maibach R, Falk S et al. Docetaxel-cisplatin-5FU (TCF) versus docetaxel-cisplatin (TC) versus epirubicin-cisplatin-5FU (ECF) in systemic treatment for advanced gastric carcinoma (AGC): A randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). Proc Am Soc Clin Oncol 2004; 23: 317 (Abstr 4020).